Sarepta Therapeutics
SRPT
17.50
+0.19
+1.10%
Sarepta Therapeutics
US · SRPT
#2853 by market cap
Listed 1970
17.50
+0.19
+1.10%
Live - 5344 symbols - heartbeat 523s ago
· 2026-10-08 08:23
Pre-market
17.50
0.00%
After-hours
17.69
+1.09%
Overnight
17.62
+0.69%
- Market cap
- 1.85B
- P/E (TTM)i
- -11.15
- P/Bi
- 1.21
- EPSi
- -7.13
- Div yieldi
- 0.00%
- 52W posi
- 28%
Reader sentiment
Are you bullish or bearish on SRPT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.2 percentage points.
Institutional ownership
- Held by institutions
- 102.80% +0.20pp
- Institutions
- 384 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund73.81%
Hedge Fund18.27%
Public Company7.24%
Individual/Insider4.78%
Private Company1.51%
Government Pension Fund1.11%
VC/PE Fund0.46%
Insurance Company0.30%
Top holders as of 2026-06-30
BlackRock
17.98% · 18.99M sh
State Street Global Advisors
8.44% · 8.92M sh
Vanguard Portfolio Management, LLC
7.93% · 8.38M sh
Vanguard Capital Management, LLC
5.01% · 5.29M sh
Two Sigma Investments, LP
4.35% · 4.60M sh
First Trust Advisors L.P.
4.13% · 4.37M sh
AQR Capital Management
4.04% · 4.27M sh
Richard Barry
3.05% · 3.22M sh
Geode Capital Management, LLC
2.62% · 2.77M sh
Erste Asset Management GmbH
2.43% · 2.57M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 24 sells
| Name | Role | Stake |
|---|---|---|
| Richard Barry | Independent Director | 3.05% |
| Michael Chambers | Independent Director | 0.46% |
| Douglas Ingram | Chief Executive Officer | 0.37% |
| M. Behrens Wilsey | Independent Chairwoman | 0.20% |
| Louise Rodino-Klapac | Executive VP, Chief Scientific Officer and Head of Research & Development | 0.19% |
| Ian Estepan | Chief Financial Officer | 0.17% |
| Ryan Wong | Chief Financial Officer | 0.12% |
| Cristin Rothfuss | -- | 0.11% |
| Claude Nicaise | Independent Director | 0.03% |
| Hans Wigzell | Chairman of Corporate Strategy Board & Independent Non-Employee Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-03 | Louise Rodino-Klapac | Executive VP, Chief Scientific Officer and Head of Research & Development | Sale to Issuer | -21,423 | $22.22 |
| 2026-09-03 | Ian Estepan | Chief Financial Officer | Sale to Issuer | -24,799 | $22.22 |
| 2026-09-03 | Cristin Rothfuss | -- | Sale to Issuer | -22,025 | $22.22 |
| 2026-09-03 | Ryan Wong | Chief Financial Officer | Sale to Issuer | -13,272 | $22.22 |
| 2026-07-27 | Michael Severino | Chief Executive Officer | Other Acquisition | +756,104 | -- |
| 2026-07-27 | Michael Severino | Chief Executive Officer | Other Derivative Acquisition | +2,224,342 | $17.74 |
| 2026-06-03 | M. Behrens Wilsey | Independent Chairwoman | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Hans Wigzell | Chairman of Corporate Strategy Board & Independent Non-Employee Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Richard Barry | Independent Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Michael Chambers | Independent Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Deirdre Connelly | Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Stephen Mayo | Independent Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Claude Nicaise | Independent Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Kathryn Boor | Independent Director | Other Acquisition | +16,875 | -- |
| 2026-03-11 | Stephen Mayo | Independent Director | Open Market Disposition | -7,239 | $17.02 |
| 2026-03-10 | Louise Rodino-Klapac | Executive VP, Chief Scientific Officer and Head of Research & Development | Sale to Issuer | -948 | $17.03 |
| 2026-03-10 | Ian Estepan | Chief Financial Officer | Sale to Issuer | -1,097 | $17.03 |
| 2026-03-10 | Cristin Rothfuss | -- | Sale to Issuer | -974 | $17.03 |
| 2026-03-10 | Ryan Wong | Chief Financial Officer | Sale to Issuer | -256 | $17.03 |
| 2026-03-08 | Louise Rodino-Klapac | Executive VP, Chief Scientific Officer and Head of Research & Development | Sale to Issuer | -1,399 | $16.95 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:23:53 · For reference only, not investment advice and not tailored to your situation.